Comparative Efficacy of Statins for Prevention of Contrast-Induced Acute Kidney Injury in Patients With Chronic Kidney Disease: A Network Meta-Analysis

@article{Zhou2019ComparativeEO,
  title={Comparative Efficacy of Statins for Prevention of Contrast-Induced Acute Kidney Injury in Patients With Chronic Kidney Disease: A Network Meta-Analysis},
  author={Xinbin Zhou and Jin Dai and Xiao-ming Xu and Zhijun Wang and Haibin Xu and Jie Chen and Yuangang Qiu and Wei Mao},
  journal={Angiology},
  year={2019},
  volume={70},
  pages={305 - 316}
}
Contrast-induced acute kidney injury (CI-AKI) is a common complication of iodinated contrast medium administration during cardiac catheterization. [...] Key Method We systematically searched several databases (including, Embase, PubMed, the Cochrane Library, and ClinicalTrials.gov) from inception to January 31, 2018. The primary outcome was occurrence of CI-AKI in patients with CKD undergoing cardiac catheterization. Both pairwise and network meta-analysis were performed.Expand
View on Wolters Kluwer
ncbi.nlm.nih.gov
15 Citations
Background Citations
5

15 Citations

Citation Type

Citation Type

A network meta-analysis on comparative efficacy of statins focusing for prevention of contrast-induced acute kidney injury in chronic kidney disease patients undergoing percutaneus coronary intervention
TLDR
A network meta-analysis was carried out to evaluate the effect of different statins in prevention of CI-AKI and also to investigate which type and dose of statins maybe the best choice specifically in CKD patients who have higher risk. Expand
Long-Term Follow-Up of Contrast-Induced Acute Kidney Injury: A Study from a Developing Country
TLDR
CI-AKI is a common complication post percutaneous catheterization (PCI), which may increase the risk for CKD, but not death or the need for recatheterization, and preventive measures must be taken early to decrease the morbidity. Expand
Is there association between statin usage and contrast-associated acute kidney injury after intravenous administration of iodine-based contrast media in enhanced computed tomography?
TLDR
Collectively, statin was not significantly associated with the risk of CI-AKI events in patients undergoing contrast-enhanced abdominopelvic CT and high-intensity statins did not show significant association with CI- AKI over low- to moderate- intensity statins in the subgroup analysis. Expand
Effect of statins on post-contrast acute kidney injury: a multicenter retrospective observational study
  • Maoning Lin, T. Xu, +6 authors Min Wang
  • Medicine
  • Lipids in health and disease
  • 2021
TLDR
Preoperative statins therapy is an independent protective factor of PC-AKI, regardless of its type, and the potential use of statins in preventing PC- AKI among those at risk is underscored. Expand
Predictors of Mortality After Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction
TLDR
The authors investigated the association between contrastinduced nephropathy (CIN) and mortality in patients with acute myocardial infarction (AMI) but they did not mention about subgroups such as ongoing ST-segment elevation myocardIAL infarctions (STEMI), ongoing non-STEMI, and stabilized AMI. Expand
Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease
TLDR
This narrative review discusses the use of hypolipidaemic drugs in patients with both CVD and CKD, and statin±ezetimibe therapy should not be initiated, but should be continued, in dialysis-treated CKD patients. Expand
Contrast-induced nephropathy in non-cardiac vascular procedures, a narrative review: Part 1.
TLDR
Physicians and vascular surgeons should be aware of CM-related adverse events and the potential strategies to avoid them, as well as preventive strategies and alternatives to limit iodinated CM use. Expand
Pharmacologic Prophylaxis of Contrast-Induced Nephropathy.
TLDR
The present update presents the latest findings in this field focusing on the changing paradigms in the definition and consequently the approach to nephroprotection that considers clinical prognosis as the major issue. Expand
Contrast-Induced Acute Kidney Injury: Review and Practical Update
TLDR
The pathophysiology, predictors, and clinical management of CI-AKI are addressed with a concise overview and a suggested association with left atrial appendage closure is suggested. Expand
Cholesterol, carotid artery disease and stroke: what the vascular specialist needs to know.
TLDR
Physicians should keep in mind the pivotal role of cholesterol levels in determining cardiovascular outcomes and the pleiotropic beneficial effects associated with statin use and should not miss the opportunity for cardiovascular risk reduction with aggressive statin treatment. Expand
...
1
2
...

References

SHOWING 1-10 OF 58 REFERENCES
Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease.
TLDR
Rosuvastatin significantly reduced the risk of CI-AKI in patients with type 2 DM and CKD undergoing arterial contrast medium injection. Expand
The Role of Statins in Preventing Contrast-Induced Acute Kidney Injury
TLDR
It is uncertain whether statins should be prescribed to prevent CI-AKI in the absence of other indications, and there are also conflicting results. Expand
Contrast-Induced Acute Kidney Injury Is Associated With Long-Term Adverse Events in Patients With Acute Coronary syndrome
TLDR
Patients with acute coronary syndrome who developed CI-AKI have worse prognosis at long-term follow-up and additional preventive treatment strategies need to be developed in this group of patients. Expand
Contrast medium induced acute kidney injury: a narrative review
TLDR
Pre-existing CKD, intra-arterial administration and CM volume are the most important risk factors for CI-AKI, and patients should be carefully stratified before the administration of CM, to reduce the negative impact of modifiable risk factors on renal function. Expand
Comparison of the Efficacy of Rosuvastatin versus Atorvastatin in Preventing Contrast Induced Nephropathy in Patient with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention
TLDR
Rosuvastatin and atorvastatin have similar efficacies for preventing CIN in patients with CKD undergoing PCI, after adjusting for potential confounding risk factors. Expand
Impact of Rosuvastatin on contrast-induced acute kidney injury in patients at high risk for nephropathy undergoing elective angiography.
TLDR
In conclusion, rosuvastatin did not reduce the risk for contrast-induced acute kidney injury or other clinically relevant outcomes in at-risk patients who underwent coronary and peripheral vascular angiography. Expand
Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome).
TLDR
High-dose rosuvastatin given on admission to statin-naïve patients with ACS who are scheduled for an early invasive procedure can prevent CI-AKI and improve short-term clinical outcome. Expand
Statins in prevention of contrast-induced nephropathy in patients with coronary heart disease and renal insufficiency undergoing percutaneous coronary intervention
TLDR
A short-term administration of high doses of atorvastatin before and after contrast exposure fails to decrease CIN occurrence in CHD patients with pre-existing renal insufficiency. Expand
Pro: Contrast-induced nephropathy—should we try to avoid contrast media in patients with chronic kidney disease?
  • M. Windpessl, A. Kronbichler
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2018
TLDR
Despite considerable progress in the field, the risk of CI-AKI is still high in the modern era and that CM-based imaging should be employed with great restraint in patients with CKD, and there is conceded that there is always a trade-off. Expand
Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
TLDR
Pretreatment with simvastatin 80 mg before PCI could further decrease the occurrence of contrast-induced nephropathy compared with simVastatin 20 mg, and this benefit was associated with the lowering of high-sensitive C-reactive protein, P-selectin, and intercellular adhesion molecule-1 levels. Expand
...
1
2
3
4
5
...